National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting, 22554-22555 [2017-09785]
Download as PDF
22554
Federal Register / Vol. 82, No. 93 / Tuesday, May 16, 2017 / Notices
Contact Person: Deborah Ismond, Ph.D.,
Scientific Review Officer, Division of
Scientific Programs, National Institute on
Minority Health, and Health Disparities,
National Institutes of Health, 7201 Wisconsin
Ave., Suite 525, Bethesda, MD 20814, (301)
594–2704, ismonddr@mail.nih.gov/.
Dated: May 10, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–09786 Filed 5–15–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Invention;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by emailing the indicated licensing
contact at the National Heart, Lung, and
Blood, Office of Technology Transfer
and Development Office of Technology
Transfer, 31 Center Drive Room 4A29,
MSC 2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive any unpublished
information.
SUPPLEMENTARY INFORMATION: The
following inventions are available for
licensing in accordance with 35 U.S.C.
209 and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Technology description
follows.
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
T-Cells Transduced With HLA A11
Restricted CT–RCC HERV–E Reactive
TCR To Treat Patients With ccRCC
Description of Technology: We
isolated an allogeneic T cell clone from
a clear cell renal cell carcinoma (ccRCC)
HLA–A11 patient who showed
prolonged tumor regression after an
allogeneic transplant. This clone was
found to have tumor specific
cytotoxicity, killing patient’s tumor cells
in vitro. We found that antigen
recognized by this clone is an HLA–A11
restricted peptide (named CT–RCC–1)
and it is encoded by a novel human
endogenous retrovirus-E (named CT–
RCC HERV–E) whose expression was
discovered to be restricted to ccRCC, but
VerDate Sep<11>2014
16:42 May 15, 2017
Jkt 241001
not observed in normal tissues or other
tumor types. We observed that more
than 80% of ccRCC tumors express CT–
RCC HERV–E provirus, which makes it
an ideal target for T cell based
immunotherapy. We have sequenced
and cloned the genes for a T cell
receptor (TCR) that specifically
recognizes an HLA–A11 restricted CT–
RCC–1 antigen. We then created a
retroviral vector encoding this TCR as
well as a truncated CD34 protein lacking
the intracellular domain, which can be
used to facilitate the isolation of T-cells
transduced with this TCR. Phase I/II
clinical trials are currently being
planned in patients with metastatic
ccRCC using normal patient’s T-cells
transduced with this vector.
Potential Commercial Applications:
The vector can be used to transduce and
expand normal T cells from HLA–A11
patients with metastatic ccRCC with the
TCR recognizing HLA–A11-restricted
CT–RCC HERV–E antigen that
specifically expressed on clear cell type
of kidney cancer. The transduced
cytotoxic T cells can then be
administered to subjects to treat or
inhibit metastatic kidney cancer. Kidney
cancer is responsible for approximately
12,000 deaths every year in the United
States alone. As with most cancer, when
detected at early stages, surgical
intervention is highly effective. Despite
progress in treating kidney cancer with
IL–2 and inhibitors of immune
checkpoints, metastatic ccRCC is
generally lethal, with mean survival
being less than a year. Patients with
melanoma and other malignancies can
now benefit from adoptive T cell
transfer. One of the limitations of this
approach for metastatic kidney cancer is
a lack of identified tumor restricted
antigens for this tumor. We show that
the CT–RCC HERV–E is expressed in
most ccRCC tumors but not in normal
tissues which makes the antigens
encoded by this provirus ideal targets
for T cell-based immunotherapy of
ccRCC.
Development Stage: Early-stage; In
vitro data available.
Inventors: Richard W. Childs and
Elena Cherkasova (NHLBI), Michael
Nishimura (Loyola University Chicago).
Publications:
1. Takahashi Y. et al. 2008. Regression
of kidney cancer following allogeneic
stem-cell transplantation associated
with T-cells recognizing a HERV–E
antigen. J. Clin. Invest. 118:1099–109.
2. Cherkasova E. et al. 2011.
Inactivation of the von Hippel-Lindau
tumor suppressor leads to selective
expression of a human endogenous
retrovirus in kidney cancer. Oncogene
30:4697–706.
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
3. Cherkasova E. et al. 2013.
Endogenous retroviruses as targets for
antitumor immunity in renal cell cancer
and other tumors. Front. Oncol. 3:243–
247.
4. Cherkasova E. et al. 2016. Detection
of a HERV–E envelope with selective
expression in clear cell kidney cancer.
Cancer Res. 76:2177–2185.
Intellectual Property: NIH Reference
No. E–120–2016/0—US Application No.
62/357,265, filed June 30, 2016.
Licensing Contact: Cristina
Thalhammer-Reyero, Ph.D., M.B.A.;
301–435–4507; thalhamc@mail.nih.gov.
Dated: May 2, 2017.
Cristina Thalhammer-Reyero,
Senior Licensing and Patenting Manager,
Office of Technology Transfer and
Development, National Heart, Lung, and
Blood Institute.
[FR Doc. 2017–09792 Filed 5–15–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
Diseases Special Emphasis Panel; AMSC
Review Conflict Meeting.
Date: June 8, 2017.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: 6701 Democracy Boulevard,
Conference Room 803, Bethesda, MD 20892.
Contact Person: Yin Liu, Ph.D., M.D.,
Scientific Review Officer, Scientific Review
Branch, NIH/National Institute of Arthritis,
Musculoskeletal and Skin Diseases, 6701
Democracy Boulevard, Suite 824, Bethesda,
MD 20892, 301–451–4838, yin.liu@.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
E:\FR\FM\16MYN1.SGM
16MYN1
Federal Register / Vol. 82, No. 93 / Tuesday, May 16, 2017 / Notices
Dated: May 9, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2017–09785 Filed 5–15–17; 8:45 am]
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
sradovich on DSK3GMQ082PROD with NOTICES
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group; Microbiology and Infectious Diseases
B Subcommittee MID–B June 2017.
Date: June 14–15, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bahia Resort Hotel, 998 West
Mission Bay Drive, San Diego, CA 92109.
Contact Person: Ellen S. Buczko, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institutes of Health/NIAID, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892–7616, 301–451–2676, ebuczko1@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 10, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–09784 Filed 5–15–17; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
16:42 May 15, 2017
Jkt 241001
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; NHLBI
Mentored Transition to Independence
Review Committee.
Date: June 8–9, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The William F. Bolger Center, 9600
Newbridge Drive, Potomac, MD 20854.
Contact Person: Giuseppe Pintucci, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7192, Bethesda, MD 20892, 301–827–7969,
Pintuccig@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: May 10, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–09783 Filed 5–15–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
22555
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Bioengineering, Technology and Surgical
Sciences.
Date: June 5, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Nikko San Francisco, 222
Mason Street, San Francisco, CA 94102.
Contact Person: Guo Feng Xu, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5122,
MSC 7854, Bethesda, MD 20892, 301–237–
9870, xuguofen@csr.nih.gov.
Name of Committee: Surgical Sciences,
Biomedical Imaging and Bioengineering
Integrated Review Group; Medical Imaging
Study Section.
Date: June 7–8, 2017.
Time: 6:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites by Hilton Denver
Intl Airport, 7001 Yampa Street, Denver, CO
80249.
Contact Person: Xiang-Ning Li, M.D.,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5112,
MSC 7854, Bethesda, MD 20892, 301–435–
1744, lixiang@csr.nih.gov.
Name of Committee: Oncology 1—Basic
Translational Integrated Review Group;
Tumor Cell Biology Study Section.
Date: June 8–9, 2017.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Alexandria Old Town, 1767
King Street, Alexandria, VA 22314.
Contact Person: Charles Morrow, M.D.,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6202,
MSC 7804, Bethesda, MD 20892, 301–408–
9850, morrowcs@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Interventions to Prevent and Treat
Addictions.
Date: June 8, 2017.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: JW Marriott New Orleans, 614 Canal
Street, New Orleans, LA 70130.
Contact Person: Kristen Prentice, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3112,
MSC 7808, Bethesda, MD 20892, 301–496–
0726, prenticekj@mail.nih.gov.
E:\FR\FM\16MYN1.SGM
16MYN1
Agencies
[Federal Register Volume 82, Number 93 (Tuesday, May 16, 2017)]
[Notices]
[Pages 22554-22555]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-09785]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and Musculoskeletal and Skin
Diseases; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Arthritis and
Musculoskeletal and Skin Diseases Special Emphasis Panel; AMSC
Review Conflict Meeting.
Date: June 8, 2017.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: 6701 Democracy Boulevard, Conference Room 803, Bethesda,
MD 20892.
Contact Person: Yin Liu, Ph.D., M.D., Scientific Review Officer,
Scientific Review Branch, NIH/National Institute of Arthritis,
Musculoskeletal and Skin Diseases, 6701 Democracy Boulevard, Suite
824, Bethesda, MD 20892, 301-451-4838, yin.liu@.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.846,
Arthritis, Musculoskeletal and Skin Diseases Research, National
Institutes of Health, HHS)
[[Page 22555]]
Dated: May 9, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-09785 Filed 5-15-17; 8:45 am]
BILLING CODE 4140-01-P